<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21756" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Filariasis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Newman</surname>
            <given-names>Thomas E.</given-names>
          </name>
          <aff>Baylor Scott and White</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Juergens </surname>
            <given-names>Andrew L.</given-names>
          </name>
          <aff>Texas A&#x00026;M</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Newman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Juergens declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21756.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lymphatic filariasis is a neglected tropical disease that causes significant morbidity in the developing world. This activity reviews the evaluation, treatment, management of lymphatic filariasis and reviews the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of lymphatic filariasis medical conditions and emergencies.</p></list-item><list-item><p>Outline the appropriate history, physical, and evaluation of lymphatic filariasis.</p></list-item><list-item><p>Review the treatment options available for lymphatic filariasis.</p></list-item><list-item><p>Describe the interprofessional team strategies for improving care coordination and communication to advance lymphatic filariasis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21756&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21756">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21756.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Filariasis is a disease caused by a chronic mosquito-borne parasitic infection. Chronic infection can lead to swelling of the extremities, hydroceles, and testicular masses.<xref ref-type="bibr" rid="article-21756.r1">[1]</xref><xref ref-type="bibr" rid="article-21756.r2">[2]</xref><xref ref-type="bibr" rid="article-21756.r3">[3]</xref>&#x000a0;It is the second-largest cause of permanent deformity and disability behind leprosy worldwide.&#x000a0;Lymphatic filariasis (LF) is currently considered a neglected tropical disease. The Global Programme to Eliminate Lymphatic Filariasis is providing mass drug administrations (MDA) to populations in endemic areas in a push to eradicate this disease.<xref ref-type="bibr" rid="article-21756.r1">[1]</xref>&#x000a0;Several programs exist to encourage participation in MDA.</p>
      </sec>
      <sec id="article-21756.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Filariasis is caused by at least three species of nematode parasites (<italic toggle="yes">Wuchereria bancrofti, Brugia malayi, and Brugia timori</italic>) and is transmitted to 5 genera of mosquitoes including <italic toggle="yes">Aedes, Anopheles, Culex, Mansonia,</italic> and <italic toggle="yes">Ochlerotatus.</italic><xref ref-type="bibr" rid="article-21756.r1">[1]</xref></p>
      </sec>
      <sec id="article-21756.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>It affects 120 million people in 72 countries worldwide, mostly in the tropics and subtropical climates of Asia, Africa, the Western Pacific, South America, and the Caribbean. Four countries in America are endemic: Haiti, the Dominican Republic, Guyana, and Brazil <xref ref-type="bibr" rid="article-21756.r4">[4]</xref>. One-third of children in endemic regions are asymptomatically infected with <italic toggle="yes">W. bancrofti.</italic><xref ref-type="bibr" rid="article-21756.r5">[5]</xref>&#x000a0;Half of the patients infected are in their 30s or 40s, and there is a 10:1 predilection for men to women.<xref ref-type="bibr" rid="article-21756.r6">[6]</xref></p>
      </sec>
      <sec id="article-21756.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Humans are the primary reservoir for this parasitic disease, and mosquitoes are the vector. The mosquito deposits larvae into the bloodstream. They take up residence in the lymph nodes and grow into adult worms. The larvae have a predilection to deposit in femoral lymph nodes. They undergo sexual reproduction, and females give birth to countless microfilariae, which are dumped into circulation in a diurnal pattern. Females can give off eggs for approximately 5 years, and adults can live up to 9 years.<xref ref-type="bibr" rid="article-21756.r6">[6]</xref>&#x000a0;With the proliferation of adult worms, the lymphatics become occluded, which disrupts the lymphatic drainage and increases the susceptibility to repeated infections - most notably streptococcal and fungal infections. This acute-on-chronic inflammation leads to fibrosis and remodeling of the lymphatics, further perpetuating contractile dysfunction and leading to the dermal skin changes seen with elephantiasis.<xref ref-type="bibr" rid="article-21756.r6">[6]</xref><xref ref-type="bibr" rid="article-21756.r7">[7]</xref></p>
      </sec>
      <sec id="article-21756.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p><italic toggle="yes">Brugia</italic> and <italic toggle="yes">Wuchereria</italic> species are similar in morphology and are the main cause of filariasis. They can be identified to the genus level using size, body wall composition, thickness, and morphology of the cuticle. The presence of small filarial worms in lymph nodes is pathognomonic for either <italic toggle="yes">Wuchereria</italic> or <italic toggle="yes">Brugia</italic>. Adult worms are typically found in lymph nodes in the groin or neck, whereas microfilariae are typically found in the peripheral blood.<xref ref-type="bibr" rid="article-21756.r8">[8]</xref></p>
        <p>The adult worms typically range in size from 45 to 100 micrometers in diameter and are typically found in lymph node cross-sections. Their descriptions include "thin, smooth cuticle which is thickened over lateral chords, three or four well-developed, low, broad muscle cells per quadrant, and relatively broad, flat lateral chords."<xref ref-type="bibr" rid="article-21756.r8">[8]</xref></p>
        <p>Microfilariae can be seen with a blood smear or other peripheral blood sample that is stained with either Giemsa or hematoxylin and eosin (H&#x00026;E) stain. The blood samples should be taken&#x000a0;after 8 pm. The microfilariae vary in size from 200 to 300 micrometers in length and 2 to 8 micrometers in diameter and are identified by the terminal and subterminal nuclei in the tail region.<xref ref-type="bibr" rid="article-21756.r8">[8]</xref></p>
      </sec>
      <sec id="article-21756.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common condition of filariasis is a hydrocele.<xref ref-type="bibr" rid="article-21756.r6">[6]</xref>&#x000a0;Children are often asymptomatic and typically present after the onset of puberty and likely into the 2nd or 3rd decade of life.<xref ref-type="bibr" rid="article-21756.r6">[6]</xref><xref ref-type="bibr" rid="article-21756.r9">[9]</xref></p>
        <p>Additional manifestations include:</p>
        <p>Filariatic fever - manifests with lymphangitis and lymphadenitis with nonspecific symptoms, including headache, fever, chills, and general malaise.&#x000a0;</p>
        <p>Filarial abscess - may form, causing localized swelling and pain until rupture, which results in the discharge of dead adult worms. Granulomatous reactions can lead to lumps in subcutaneous tissues.<xref ref-type="bibr" rid="article-21756.r6">[6]</xref>&#x000a0;</p>
        <p>Acute dermatolymphangioadenitis (ADL) - repeated bouts of lymphangitis causing lymphedema.&#x000a0;</p>
        <p>Lymphedema - graded based on the extent of the condition</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade I: Extremity pitting edema, reversible</p>
          </list-item>
          <list-item>
            <p>Grade II: Extremity pitting or nonpitting edema, nonreversible</p>
          </list-item>
          <list-item>
            <p>Grade II: Nonpitting, nonreversible edema, with skin thickening</p>
          </list-item>
          <list-item>
            <p>Grade IV: Nonpitting, nonreversible, thickened, and nodular appearance of the skin, classified as elephantiasis.<xref ref-type="bibr" rid="article-21756.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>Tropical pulmonary eosinophilia - an immune response to filarial infection. It causes pulmonary restrictive lung disease, wheezing, shortness of breath, and eosinophilia.<xref ref-type="bibr" rid="article-21756.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21756.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Peripheral smear &#x02013; The Centers for Disease Control (CDC) recommends preparing two thick and thin peripheral blood smear samples taken from either venipuncture or finger/heel stick. These are preferably taken after 8 pm given the night periodicity of microfilariae and stained with either Giemsa or H&#x00026;E stain.<xref ref-type="bibr" rid="article-21756.r6">[6]</xref>&#x000a0;</p>
        <p>PCR - for detecting antigen. Antigen detection is the preferred method of diagnosis since it also detects latent infections. However, assays for the parasite antigen of <italic toggle="yes">W. bancrofti</italic> are currently not approved by the FDA.</p>
        <p>Scrotal ultrasound - may reveal movements of adult worms in otherwise asymptomatic males. The "filarial dance sign" is a pattern of worm movement that can be detected in the lymphatic vessels of infected men.<xref ref-type="bibr" rid="article-21756.r10">[10]</xref></p>
      </sec>
      <sec id="article-21756.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Medical treatments</bold>
</p>
        <p>Diethylcarbamazine (DEC) has traditionally been recommended as potential monotherapy; however, it is to be avoided if there is coinfection with <italic toggle="yes">Loa loa</italic> or onchocerciasis as it can worsen the progression of eye disease and can cause encephalopathy.<xref ref-type="bibr" rid="article-21756.r1">[1]</xref><xref ref-type="bibr" rid="article-21756.r6">[6]</xref>&#x000a0;A single combined dose of ivermectin, albendazole, and DEC resulted in clearance of microfilaria in 96% of affected patients for up to 3 years and is currently recommended by the World Health Organization (WHO) as triple therapy in areas not endemic with <italic toggle="yes">Loa loa.</italic><xref ref-type="bibr" rid="article-21756.r11">[11]</xref>&#x000a0;Doxycycline is preferred in areas co-endemic with <italic toggle="yes">Loa loa</italic> and has also shown the ability to slow the inflammation and fibrosis that leads to worsening lymphedema. Doxycycline also treats <italic toggle="yes">Wolbachia</italic>, a genus of symbiotic bacteria that inhabit nematodes.<xref ref-type="bibr" rid="article-21756.r1">[1]</xref><xref ref-type="bibr" rid="article-21756.r12">[12]</xref></p>
        <p>There is currently no vaccine for filariasis, but efforts are ongoing to develop one.<xref ref-type="bibr" rid="article-21756.r13">[13]</xref></p>
        <p>
<bold>Surgical treatments</bold>
</p>
        <p>Surgical treatments exist for the debulking of skin and creating lymphovenous anastomosis to improve drainage.&#x000a0;Topical coumarin and flavonoids were shown to be effective in reducing lymphedema. It is thought that increased macrophage activity leads to the reuptake of proteinaceous material.<xref ref-type="bibr" rid="article-21756.r9">[9]</xref>&#x000a0;</p>
        <p>A case report documented the success of ablative carbon dioxide laser treatment of skin lesions and lymphocutaneous fistulas, which resulted in significant improvement of skin lesions. It works by causing thermal damage to the dermis, resulting in the remodeling of superficial tissue and dermal tightening. This was done in a patient with non-filarial elephantiasis but could have an application in filarial disease.<xref ref-type="bibr" rid="article-21756.r14">[14]</xref></p>
        <p>
<bold>Chronic Management</bold>
</p>
        <p>Lymphedema can progress due to repeated attacks of adenolymphangitis, even in the absence of LF. Strategies targeting lymphedema progression include working with patients on skin hygiene, wearing comfortable shoes, using compressive bandages, pneumatic compression, regular washing with soap and water, limb elevation, cold/heat therapy, and antibiotic and antifungal creams to prevent flares of lymphangitis.<xref ref-type="bibr" rid="article-21756.r9">[9]</xref><xref ref-type="bibr" rid="article-21756.r15">[15]</xref><xref ref-type="bibr" rid="article-21756.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21756.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis includes&#x000a0;<xref ref-type="bibr" rid="article-21756.r8">[8]</xref><xref ref-type="bibr" rid="article-21756.r9">[9]</xref><xref ref-type="bibr" rid="article-21756.r8">[8]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Several zoonotic filariasis, including <italic toggle="yes">Onchocerca,&#x000a0;</italic><italic toggle="yes">Dirofilaria, Brugia, Dipetalonema, Loaina, Meningonema</italic></p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Testicular neoplasms</p>
          </list-item>
          <list-item>
            <p>Congenital abnormalities of lymphatics</p>
          </list-item>
          <list-item>
            <p>Pelvic malignancy</p>
          </list-item>
          <list-item>
            <p>Damage to the lymph system secondary to surgery or radiation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21756.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>The Global Programme to Eliminate Lymphatic Filariasis is aiming to eradicate filariasis by 2020. They are currently monitoring, mapping, and mass distributing drugs to endemic areas. An update provided from this program in 2010 reports reaching the halfway point towards eliminating filariasis. As of 2015, a total of 6.2 billion treatments were delivered to over 820 million people. According to WHO data, as of 12/2019, the following countries have eliminated lymphatic filariasis as a public health problem: Egypt, Yemen, Thailand, Vietnam, Cambodia, and Sri Lanka.</p>
      </sec>
      <sec id="article-21756.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis is good if filariasis is recognized early and treated in a timely fashion to prevent deformity. The disease typically responds to 5 annual doses of DEC with or without ivermectin or albendazole. Symptoms don&#x02019;t present until later into adulthood and correlate with increasing worm burden.&#x000a0;Elephantiasis is the most severe form and is due to many years of acute on chronic superimposed infections. There is some ability to treat lymphedema, but it is difficult to manage once reaching advanced stages of the disease.</p>
      </sec>
      <sec id="article-21756.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Occult filariasis - infection of other tissues without evidence in blood.<xref ref-type="bibr" rid="article-21756.r6">[6]</xref>&#x000a0;It can lead to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tropical pulmonary eosinophilia</p>
          </list-item>
          <list-item>
            <p>Filarial arthritis</p>
          </list-item>
          <list-item>
            <p>Filarial-associated immune complex glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Filarial breast abscesses</p>
          </list-item>
        </list>
        <p>Loiasis - co-endemic infection. It can cause severe drug interactions, including encephalopathy if treated with ivermectin.<xref ref-type="bibr" rid="article-21756.r16">[16]</xref></p>
        <p>Adverse effects after receiving targeted medical therapy are likely related to systemic inflammation from filarial activity. Complications reported include fever, chills, and some hemodynamic changes, including changes to systolic blood pressure with no frank hypotension.<xref ref-type="bibr" rid="article-21756.r17">[17]</xref></p>
      </sec>
      <sec id="article-21756.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Lymphatic filariasis is rare in the United States. DEC is no longer approved by the FDA, and providers will need CDC assistance with obtaining appropriate medications and also with the confirmation of infection.&#x000a0;Patients with a coinfection of onchocerciasis with high levels of microfilaria should have a tropical medicine consultation.</p>
      </sec>
      <sec id="article-21756.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>WHO-supported strategies for vector control include insecticide-treated nets, indoor spraying, personal protection, and mass drug administration for at-risk individuals.</p>
        <p>Travelers are at little risk for developing lymphatic filariasis as it takes years of multiple exposures from infected mosquitoes to establish infection in humans, given lack of reproduction in mosquitoes.<xref ref-type="bibr" rid="article-21756.r1">[1]</xref></p>
      </sec>
      <sec id="article-21756.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Lymphatic filariasis is a rare but disfiguring disease that can lead to marked morbidity if not considered. Several diagnostic and treatment recommendations are listed above. Physicians will have to work in tandem with nursing, administration, and public health officials in both confirming the diagnosis and successfully treating patients. Depending on the severity of disfigurement, they may require additional surgical consultation. The patient may need wound care, further education in hygiene, and continued follow-up to prevent further attacks, which would lead to worse outcomes.</p>
      </sec>
      <sec id="article-21756.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21756&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21756">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/filariasis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21756">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21756/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21756">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21756.s18">
        <fig id="article-21756.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Photomicrograph, nematode, Brugia malayi, lymphatic filariasis, Parasitic diseases, Pathology, Nematode Infection Contributed by Dr. Lee Moore, The Centers for Disease Control and Prevention (CDC)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="15246_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21756.s19">
        <title>References</title>
        <ref id="article-21756.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rebollo</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Bockarie</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Can Lymphatic Filariasis Be Eliminated by 2020?</article-title>
            <source>Trends Parasitol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>83</fpage>
            <page-range>83-92</page-range>
            <pub-id pub-id-type="pmid">27765440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maldjian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Then</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yassin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Lymphatic filariasis disseminating to the upper extremity.</article-title>
            <source>Case Rep Radiol</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>985680</fpage>
            <pub-id pub-id-type="pmid">24707427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shukla</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kusum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kandari</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Filariasis presenting as a solitary testicular mass.</article-title>
            <source>Trop Parasitol</source>
            <year>2019</year>
            <season>Jul-Dec</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>124</fpage>
            <page-range>124-126</page-range>
            <pub-id pub-id-type="pmid">31579667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lourens</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Ferrell</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Lymphatic Filariasis.</article-title>
            <source>Nurs Clin North Am</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-192</page-range>
            <pub-id pub-id-type="pmid">31027660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ottesen</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Lymphatic filariasis: an infection of childhood.</article-title>
            <source>Trop Med Int Health</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>8</issue>
            <fpage>582</fpage>
            <page-range>582-606</page-range>
            <pub-id pub-id-type="pmid">11555425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chandy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Manigauha</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A review of neglected tropical diseases: filariasis.</article-title>
            <source>Asian Pac J Trop Med</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>7</issue>
            <fpage>581</fpage>
            <page-range>581-6</page-range>
            <pub-id pub-id-type="pmid">21803313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakraborty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gurusamy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zawieja</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Muthuchamy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lymphatic filariasis: perspectives on lymphatic remodeling and contractile dysfunction in filarial disease pathogenesis.</article-title>
            <source>Microcirculation</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>349</fpage>
            <page-range>349-64</page-range>
            <pub-id pub-id-type="pmid">23237232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orihel</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Eberhard</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Zoonotic filariasis.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>366</fpage>
            <page-range>366-81</page-range>
            <pub-id pub-id-type="pmid">9564568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shenoy</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Clinical and pathological aspects of filarial lymphedema and its management.</article-title>
            <source>Korean J Parasitol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>119</fpage>
            <page-range>119-25</page-range>
            <pub-id pub-id-type="pmid">18830049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marfo-Debrekyei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dittrich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adjei</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hoerauf</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis.</article-title>
            <source>Filaria J</source>
            <year>2003</year>
            <month>Feb</month>
            <day>27</day>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <pub-id pub-id-type="pmid">12636874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjerum</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ouattara</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Aboulaye</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kouadio</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Marius</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Koudou</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in C&#x000f4;te d'Ivoire: An Open-label Randomized Controlled Trial.</article-title>
            <source>Clin Infect Dis</source>
            <year>2020</year>
            <month>Oct</month>
            <day>23</day>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>e68</fpage>
            <page-range>e68-e75</page-range>
            <pub-id pub-id-type="pmid">31641754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hoerauf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bockarie</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lymphatic filariasis and onchocerciasis.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Oct</month>
            <day>02</day>
            <volume>376</volume>
            <issue>9747</issue>
            <fpage>1175</fpage>
            <page-range>1175-85</page-range>
            <pub-id pub-id-type="pmid">20739055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalyanasundaram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chauhan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Advances in Vaccine Development for Human Lymphatic Filariasis.</article-title>
            <source>Trends Parasitol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>195</fpage>
            <page-range>195-205</page-range>
            <pub-id pub-id-type="pmid">31864894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robinson</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>The Successful Treatment of Elephantiasis Nostras Verrucosa With Ablative Carbon Dioxide Laser.</article-title>
            <source>J Cutan Med Surg</source>
            <year>2018</year>
            <season>Nov/Dec</season>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>611</fpage>
            <page-range>611-613</page-range>
            <pub-id pub-id-type="pmid">29519146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stocks</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Addiss</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Hygiene-Based Lymphedema Management in Lymphatic Filariasis-Endemic Areas: A Systematic Review and Meta-analysis.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>e0004171</fpage>
            <pub-id pub-id-type="pmid">26496129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gardon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gardon-Wendel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Demanga-Ngangue</surname>
              </name>
              <name>
                <surname>Kamgno</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chippaux</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Boussinesq</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.</article-title>
            <source>Lancet</source>
            <year>1997</year>
            <month>Jul</month>
            <day>05</day>
            <volume>350</volume>
            <issue>9070</issue>
            <fpage>18</fpage>
            <page-range>18-22</page-range>
            <pub-id pub-id-type="pmid">9217715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21756.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersen</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Rosa</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kupritz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meite</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Mitreva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>e0007697</fpage>
            <pub-id pub-id-type="pmid">31557154</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
